Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
SLC2A10 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 10 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A9 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 9 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A8 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 8 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A7 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A6 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A5 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A4 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A3 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A2 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A1 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC14 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 14 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC12 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 12 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.